Conservative management of epithelial ovarian cancer

We are currently faced with a progressive delay in the age at which women conceive for the first time. This raises the possibility of the appearance of gynecologic disorders that may affect fertility, including neoplasms of the ovary. Fertility-sparing surgery is defined as the preservation of ovarian tissue in one or both adnexa and/or the uterus. Borderline ovarian tumor should be treated with conservative surgery. Salpingo-oophorectomy, or even ovarian cystectomy, are the procedures of choice, with recurrence rates of 2-3% and up to 20% if a simple cystectomy is performed. Cystectomy is indicated in patients with bilateral borderline tumors or in patients with a residual ovary. Borderline tumors with invasive peritoneal implants behave as an invasive cancer in 10-30% of cases with a survival rate of 10-66% compared with 100% in borderline tumors without invasive implants. Prophylactic oophorectomy is recommended when desire of conception has been accomplished. Conservative surgery in invasive epithelial ovarian cancer is limited to Stage IA, grade 1 tumor, and in some highly selected grade 2 tumors of serous, mucinous or endometrioid type, well-encapsulated and free of adhesions. The standard oncological surgical procedure with preservation of the uterus and normal appearing ovary is recommended. This includes salpingo-oophorectomy, excision of any suspicious peritoneal lesion, multiple peritoneal biopsies, appendectomy (particularly in mucinous tumors), and pelvic and paraaortic lymphadenectomy.

Ovarian cancer; Surgery of the ovary; Conservative surgery of ovarian cancer; Borderline ovarian tumor

[1] Dexeus S., Pascual A.: "Cribado ovarico: luna utopia?". Prog. Obstet. Ginecol., 2001, 44, 517.

[2] Morice P., Camatte S., Wicart-Poque F., Atallah D., Rouzier R., Pautier P. et al.: "Results of conservative management of epithelial malignant and borderline ovarian tumours". Hum. Reprod. Update, 2003, 9, 185.

[3] Eltabbakh G.H., Natarajan N., Piver M.S., Mettlin C.J.: "Epidemiologic differences between women with borderline ovarian tumors and women with epithelial ovarian cancer". Gynecol. Oneal., 1999, 74, 103.

[4] Trimble C.L., Kosary C., Trimble E.L.: "Long-term survival and patterns of care in women with ovarian tumors of low malignant potential" Gynecol. Oneal., 2002, 86, 34.

[5] Duska L.R., Chang Y.C., Flynn C.E., Chen A.H., Goodman A., Fuller A.F. et al.: "Epithelial ovarian carcinoma in the reproductive age group" Cancer, 1999, 85, 2623.

[6] Crispens M.A., Bodurka D., Deavers M., Lu K., Silva E.G., Gershenson D.M.: "Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential". Obstet. Gynecol., 2002, 99, 3.

[7] Seidman J.D., Kurman R.J.: "Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases". Am. J. Surg. Pathol., 1996, 20, 1331.

[8] Prat J., De Nictolis M.: "Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion". Am. J. Surg. Pathol., 2002, 26, 1111.

[9] Trope C., Kaern J.: "Management of borderline tumors of the ovary: state of the art". Semin. Oneal., 1998, 25, 372.

[10] Nielsen J.S., Jakobsen E., Holund B., Bertelsen K., Jakobsen A.: "Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer". Int. J. Gynecol. Cancer, 2004, 14, 1086.

[11] Heinrich J.K., Bottcher-Luiz F., Andrade L.L., Davidson S., Bonds L., Stephens J. et al.: "HER-2 and cancer antigen 125 evaluation in ovanan borderline tumors by immunohistochemistry and fluorescence in situ hybridization". Int. J. Gynecol. Cancer, 2004, 14, 1078.

[12] Sanz Casla M.T., Vidaurreta Lazaro M., Almansa de Lara I., Tresserra F., Lopez Marin L., Maestro M.L. et al.: "Role of microsatellite instability in borderline ovarian tumors". Anticancer Res., 2003, 23, 5139.

[13] Sood A.K., Holmes R., Hendrix M.J., Buller R.E.: "Application of the National Cancer Institute international criteria for determination of microsatellite instab山ty in ovarian cancer". Cancer Res., 2001, 61, 4371.

[14] Hernandez G., Cusid6 M.T.: "Resultados de la encuesta nacional 1990-1997 tumores borderline de ovario". Palma de Mallorca, October 8, 2004.

[15] Julian C.G., Woodruff J.D.: "The biologic behavior of low-grade papillary serous carcinoma of the ovary". Obstet. Gynecol., 1972, 40, 860.

[16] Zanetta G., Rota S., Chiari S., Bonazzi C., Bratina G., Mangioni C.: "Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study". J. Clin. Oneal., 2001, 19, 2658.

[17] Papadimitriou D.S., Martin-Hirsch P.,Kitchener H.C., Lolis D.E., Dalkalitsis N., Paraskevaidis E.: "Recurrent borderline ovarian tumours after conservative management in women wishing to retain their fertility". Eur. J. Gynaecol. Oneal., 1999, 20, 94.

[18] Camatte S., Morice P., Pautier P., Atallah D., Duvillard P., Castaigne D.: "Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary". Br. J. Obstet. Gynecol., 2002, 109, 376.

[19] Lin P.S., Gershenson D.M., Bevers M.W., Lucas K.R., Burke T.W., Silva E.G.: "The current status of surgical staging of ovarian serous borderline tumors". Cancer, 1999, 85, 905.

[20] Tusquets I., Serra B., Treserra F. et al.: "Tumor seroso borderline ovarico con afectaci6n ganglionar pelvica sincr6nica". Prog. Obstet. Ginecol., 1996, 39, 370.

[21] Leake J.F., Currie J.L., Rosenshein N.B., Woodruff J.D.: "Long-term follow-up of serous ovarian tumors of low malignant potential". Gynecol. Oneal., 1992, 47, 150.

[22] Dexeus S., Cusido M.T., Suris J.C., Grases P., Paraira M.: "Lymphadenectomy in ovarian cancer". Eur. J. Gynaecol. Oneal., 2000, 21, 215.

[23] Darai E., Teboul J., Fauconnier A., Scoazec J.Y., Benifla J.L., Madelena! P.: "Management and outcome of borderline ovarian tumors incidentally discovered at or after laparoscopy". Acta Obstet. Gynecol. Scand., 1998, 77, 451.

[24] Gershenson D.M.: "Contemporary treatment of borderline ovarian tumors". Cancer Invest., 1999, 17, 206.

[25] Gershenson D.M., Silva E.G., Levy L., Burke T.W., Wolf J.K., Tornos C.: "Ovarian serous borderline tumors with invasive peritoneal implants". Cancer, 1998, 82, 1096.

[261 Morice P., Camatte S., El Hassan J., Pautier P., Duvillard P., Castaigne D.: "Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors". Fertil. Steril., 2001, 75, 92.

[27] Gotlieb W.H., Flikker S., Davidson B., Korach Y., Kopolovic J., Ben-Baruch G.: "Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome". Cancer, 1998, 82, 141.

[28] Morris R.T., Gershenson D.M., Silva E.G., Follen M., Morris M., Wharton J.T.: "Outcome and reproductive function after conservative surgery for borderline ovarian tumors". Obstet. Gynecol., 2000, 95, 541.

[29] Shushan A., Paltiel O., lscovich J., Elchalal U., Peretz T., Schenker J.G.: "Human menopausal gonadotropin and the risk of epithelial ovanan cancer". Fertil. Steril., 1996, 65, 13.

[30] Cusid6 M.,S as A.,T reserras F.,G rases P.,L abastida R.: "Tumor epitelial limftrofe (borderline) del ovario: estudio de 33 casos". Prag. Obstet Ginecol., 1999, 42, 447.

[31] Balasch J., Barri P.N.: "Follicular stimulation and ovarian cancer?". Hum. Reprod., 1993, 8, 990.

[32] Ayhan A., Celik H., Taskiran C., Bozdag G., Aksu T.: "Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer" Eur. J. Gynaecol. Oneal., 2003, 24, 223.

[33] Benedetti-Panici P., Greggi S., Maneschi F., Scambia G., Amoroso M., Rabitti C. et al.: "Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer". Gynecol. Oneal., 1993, 51, 150.

[34] Suzuki M., Ohwada M., Yamada T., Kohno T., Sekiguchi I., Sato I.: "Lymph node metastasis in Stage I epithelial ovarian cancer". Gynecol. Oncol., 2000, 79, 305.

[35] Cass I., Li A.J., Runowicz C.D., Fields A.L., Goldberg G.L., Leuchter R.S. et al.: "Pattern of lymph node metastases in clinically unilateral Sage I invasive epithelial ovarian carcinomas". Gynecol. Oncol., 2001, 80, 56.

[36] Morice P., Wicart-Poque F., Rey A., El-Hassan J., Pautier P., Lhorrune C. et al.: "Results of conservative treatment in epithelial ovarian carcinoma". Cancer, 2001, 92, 2412.

[37] Zanetta G., Chiari S., Rota S., Bratina G., Maneo A., Torri V. et al.: "Conservative surgery for Stage I ovarian carcinoma in women of childbearing age". Br. J. Obstet. Gynaecol., 1997, 104, 1030.

[38] Benjamin I., Morgan M.A., Rubin S.C.: "Occult bilateral involvement in Stage I epithelial ovarian cancer". Gynecol. Oneal., 1999, 72, 288.

[39] Tozzi R., Kohler C., Ferrara A., Schneider A.: "Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes". Gynecol Oncol., 2004, 93, 199

[40] Lecuru F., Desfeux P., Camatte S., Bissery A., Robin F., Blanc B., et al.: "Stage I ovarian cancer: comparison of laparoscopy and laparotomy on staging and survival". Eur. J. Gynaecol. Oneal., 2004, 25, 571.

[41] Colombo N., Chiari S., Maggioni A., Bocciolone L., Torri V., Mangioni C.: "Controversial issues in the management of early epithelial ovanan cancer: conservative surgery and role of adjuvant therapy". Gynecol. Oncol., 1994, 55, S47.

[42] Vergote I., De Brabanter J., Fyles A., Bertelsen K., Einhorn N., Sevelda P. et al.: "Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma". Lancet, 2001, 357, 176.

[43] Morice P., Wicart-Poque F., Rey A., Camatte S., Rouzier R., Pautier P. et al.: "Results and fertility after conservative treatment of mvasive epithelial ovarian cancer". Gynecol. Obstet. Fertil., 2002, 30, 684.